• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Lentiviral gene therapy treatment for adenosine deaminase deficiency

bySze Wah Samuel ChanandHarsh Shah
June 25, 2021
in Gastroenterology, Hematology, Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with autologous CD34+ hematopoietic stem and progenitor cells transduced with human ADA via a lentiviral vector showed sustained ADA expression in patients with severe combined immunodeficiency from adenosine deaminase deficiency.

2. The lentiviral treatment showed persistent engraftment and nearly all patients discontinued immunoglobulin-replacement therapy.

Evidence Rating Level: 2 (Good)    

Study Rundown: Severe combined immunodeficiency due to adenose deaminase (ADA-SCID) is a disease of inborn errors of metabolism resulting in severely impaired immune function. Current treatments include enzyme-replacement therapy which does not fully repair the immune system or hematopoietic stem-cell transplant which carries infection or graft-vs-host disease risk. This study evaluated the efficacy and safety of autologous lentivirus-mediated transduction of ADA into CD34+ hematopoietic and progenitor cells as a treatment for immunodeficiency. The study determined a high event-free survival defined as the absence of enzyme-replacement therapy or rescue transplant. The study reported 90% of patients stopped receiving immunoglobulin-replacement therapy at 24 months in the United States cohort, while in the United Kingdom cohort, all patients no longer needed immunoglobulin therapy at 36 months. The main limitation of this study was the single-arm nature and lack of a comparator to the standard of care. Nonetheless, the study’s results are significant showing autologous stem-cell transplant has a comparable effect to the standard of care therapies without the need for continued immunosuppression.

Click here to read the study in the NEJM

Relevant Reading: Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

RELATED REPORTS

AAV gene therapy shows durable benefit in hemophilia B

AAV9.LAMP2B gene therapy shows clinical benefit in Danon disease

#VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis

In-Depth [prospective cohort]: This was a single-arm, multi-center, of three prospective cohorts from the United States and the United Kingdom. Across the three cohorts, 50 patients were enrolled in the study. Children diagnosed with ADA-SCID and at least one month of age or older were included in the United States study. Children diagnosed with ADA-SCID and either younger than five years of age or between the ages of five and 15 with preserved thymic function were included in the United Kingdom study. For all three cohorts, children with an HLA-matched sibling were excluded from the studies. All patients were treated with autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) which were transduced with the human ADA gene via a self-inactivating lentiviral vector. The primary efficacy endpoints were overall survival and event-free survival at 12 months. In all studies, overall survival was 100% at 24 and 36 months. Event-free survival was 97% in the United States and 100% in the United Kingdom at 12 months. At 24 months, 90% of patients in the United States no longer needed immunoglobulin therapy, while at 36 months, 100% of patients in the United Kingdom had stopped replacement therapy. There were no reported cases of monoclonal expansion, oncogenic adverse events, or replication of pathogenic lentivirus. Furthermore, no reports of autoimmunity or graft-versus-host emerged. The most common adverse events were infections, pyrexia, and gastrointestinal events. Overall, this study demonstrated the feasibility of using ex vivo edited autologous CD34+ HSPCs for ADA-SCID treatment.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenosine deaminase deficiency (ADA)CD34gene therapylentivirussevere combined immunodeficiency (SCID)
Previous Post

Shorter antibiotic therapy for prosthetic joint infection caused worse outcomes

Next Post

#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

RelatedReports

Primary thromboembolism prophylaxis may be effective in advanced cancer
Hematology

AAV gene therapy shows durable benefit in hemophilia B

July 7, 2025
Cardiology

AAV9.LAMP2B gene therapy shows clinical benefit in Danon disease

March 14, 2025
#VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis
StudyGraphics

#VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis

October 9, 2024
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Pharma

Taysha Gene Therapies: TSHA-102 Gene Therapy Improves Quality of Life in Patients with Rett Syndrome

June 26, 2024
Next Post
#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

Few older adolescents meet recommended levels of physical activity

Consistent physical inactivity may increase the severity of COVID-19 infection

Palliative chemotherapy associated with more ICU treatment at end-of-life

Hospital admission rates for non-COVID-19 diseases have decreased since start of pandemic in Denmark

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.